En esta página
01BOLD precio
02Instantánea
03Gráfico
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
26Mis Métricas
BOLD Boundless Bio, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 7, 2026
$2,62
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$1,00mínimo 52 semanas
$3,16máximo 52 semanas
Capitalización Bursátil (MRQ)
$59M
P/E
-1.0
BPA
$-2.60
tus insignias
Rango 52S
$1–$3
Calificación del Analista
HOLD
Precio Objetivo
$4
P/E
-1.0
ROE
-46.7%
Margen de Beneficio Neto
·
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
BOLD Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$2.62
Capitalización Bursátil (MRQ)
$59M
P/E
-1.0
BPA
$-2.60
ROE
-46.7%
Rango 52S
$1–$3
BOLD Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Acerca de Boundless Bio, Inc. - Common Stock Descripción general de la empresa de Wikipedia
sectorHealthcare
industriaBiotechnology
empleados28
paísUS
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
BPA$-2.602023-12-31 → 2025-12-31
Flujo de caja libre$-47M2024-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | BOLD | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -1.0 | · | · | · | |
| P/C (MRQ) | 0.9 | · | 1.6 | Infravalorado | |
| Precio / FCF (TTM) | -1.0 | · | · | · | |
| Precio / Flujo de Caja (TTM) | -1.0 | · | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 0.6 | · | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | BOLD | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -32.0% | · | -106.0% | De primer nivel | |
| ROE | -46.7% | · | -116.7% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | BOLD | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 9.5 | · | 3.9 | Liquidez sólida | |
| Quick Ratio (Ratio Rápido) | 8.6 | · | 3.2 | Liquidez sólida |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-12.9%
Próximo informe
Nov 03, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 17, 2026 | $-1.06 | $-0.59 | -79.2% |
| 31 de marzo de 2026 | May 18, 2026 | $-0.60 | $-0.59 | -2.0% |
| 31 de diciembre de 2025 | $-0.58 | $-0.53 | -9.4% | |
| 30 de septiembre de 2025 | $-0.62 | $-0.59 | -4.3% | |
| 30 de junio de 2025 | $-0.70 | $-0.66 | -5.6% | |
| 31 de marzo de 2025 | $-0.71 | $-0.75 | 5.3% | |
| 31 de diciembre de 2024 | $-0.74 | $-0.78 | 4.8% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $45M | $55M | $43M | |
| SG&A Expense | $19M | $18M | $12M | |
| Operating Expenses | $64M | $73M | $55M | |
| Operating Income | $-64M | $-73M | $-55M | |
| Interest Income | $5M | $8M | $5M | |
| Other Non-op | $-2.0K | $12.0K | $80.0K | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-58M | $-65M | $-49M | |
| EPS (Basic) | $-2.60 | $-3.85 | $-40.65 | |
| EPS (Diluted) | $-2.60 | $-3.85 | $-40.65 | |
| Shares (Basic) | 22,360,000 | 16,984,000 | 1,216,000 | |
| Shares (Diluted) | 22,360,000 | 16,984,000 | 1,216,000 | |
| EBITDA | $-62M | $-72M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $18M | $27M | $24M | |
| Short-term Investments | $90M | $126M | $97M | |
| Prepaid Expense | $2M | $2M | $3M | |
| Current Assets | $110M | $154M | $124M | |
| PP&E (Net) | $3M | $4M | $3M | |
| PP&E (Gross) | $8M | $8M | $5M | |
| Accum. Depreciation | $5M | $4M | $3M | |
| Total Assets | $157M | $206M | $130M | |
| Accounts Payable | $1M | $1M | $2M | |
| Current Liabilities | $13M | $8M | $9M | |
| Capital Leases | $46M | $48M | · | |
| Total Liabilities | $58M | $56M | $9M | |
| Common Stock | $2.0K | $2.0K | $0 | |
| Paid-in Capital | $358M | $352M | $9M | |
| Retained Earnings | $-260M | $-201M | $-136M | |
| AOCI | $64.0K | $121.0K | $40.0K | |
| Stockholders' Equity | $99M | $151M | $-127M | |
| Liabilities + Equity | $157M | $206M | $130M | |
| Shares Outstanding | 22,407,000 | 22,300,000 | 1,248 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| D&A | $1M | $1M | $957.0K | |
| Stock-based Comp | $6M | $8M | $3M | |
| Deferred Tax | $0 | · | · | |
| Other Non-cash | $4M | $-4M | · | |
| Operating Cash Flow | $-47M | $-61M | $-47M | |
| CapEx | $546.0K | $3M | $633.0K | |
| Investing Cash Flow | $38M | $-26M | $-38M | |
| Financing Cash Flow | $141.0K | $90M | $98M | |
| Net Change in Cash | $-9M | $3M | $13M | |
| Free Cash Flow | $-47M | $-63M | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -32.0% | -38.9% | · | |
| ROE | -46.7% | -554.9% | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 8.7 | 19.0 | · | |
| Quick Ratio | 8.6 | 18.7 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Book Value / Share | $4.40 | $6755.25 | · | |
| Cash Flow / Share | $-2.09 | $-3.58 | · | |
| Cash / Share | $0.80 | $1192.24 | · | |
| EPS (TTM) | $-2.60 | $-3.85 | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-58M | $-65M | · | |
| Market Cap | $27M | $64.7K | · | |
| P/E | -0.5 | -0.8 | · | |
| P/B | 0.3 | 0.0 | · | |
| P / Tangible Book | 0.3 | 0.0 | · | |
| P / Cash Flow | -0.6 | -0.0 | · | |
| P / FCF | -0.6 | -0.0 | · | |
| Earnings Yield | -216.7% | -132.8% | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $14M | $10M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $13M | $10M | $12M | $11M | $10M | |
| SG&A Expense | $10M | $5M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | $3M | $3M | $3M | |
| Operating Expenses | $24M | $14M | $14M | $15M | $17M | $17M | $18M | $19M | $19M | $17M | $14M | $15M | $14M | $12M | |
| Operating Income | $-24M | $-14M | $-14M | $-15M | $-17M | $-17M | $-18M | $-19M | $-19M | $-17M | $-14M | $-15M | $-14M | $-12M | |
| Interest Income | $690.0K | $920.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $395.0K | |
| Other Non-op | $1.0K | · | $0 | $0 | $0 | $-2.0K | $-85.0K | $32.0K | $33.0K | $32.0K | $64.0K | $32.0K | $11.0K | $-27.0K | |
| Net Income | $-24M | $-14M | $-13M | $-14M | $-16M | $-16M | $-16M | $-17M | $-17M | $-15M | $-12M | $-13M | $-12M | $-12M | |
| EPS (Basic) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | $-10.71 | $-10.28 | $-9.91 | |
| EPS (Diluted) | $-1.06 | $-0.60 | $-0.57 | $-0.62 | $-0.70 | $-0.71 | $9.93 | $-0.74 | $-0.77 | $-12.27 | $-9.75 | $-10.71 | $-10.28 | $-9.91 | |
| Shares (Basic) | 22,450,000 | 22,407,000 | · | 22,386,000 | 22,356,000 | 22,300,000 | · | 22,254,000 | 22,023,000 | 1,258,000 | · | 1,230,000 | 1,206,000 | 1,183,000 | |
| Shares (Diluted) | 22,450,000 | 22,407,000 | · | 22,386,000 | 22,356,000 | 22,300,000 | · | 22,254,000 | 22,023,000 | 1,258,000 | · | 1,230,000 | 1,206,000 | 1,183,000 | |
| EBITDA | $-24M | $-14M | · | $-15M | $-17M | $-17M | · | $-19M | $-19M | $-17M | · | · | · | · |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20M | $17M | $18M | $15M | $15M | $15M | $27M | $40M | $31M | $25M | $24M | · | · | · | |
| Short-term Investments | $52M | $75M | $90M | $103M | $112M | $123M | $126M | $127M | $148M | $80M | $97M | · | · | · | |
| Prepaid Expense | $1M | $2M | $2M | $3M | $3M | $2M | $2M | $3M | $4M | $7M | $3M | · | · | · | |
| Current Assets | $74M | $95M | $110M | $120M | $130M | $140M | $154M | $170M | $183M | $112M | $124M | · | · | · | |
| PP&E (Net) | $97.0K | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $2M | $3M | · | · | · | |
| PP&E (Gross) | $4M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $5M | $5M | · | · | · | |
| Accum. Depreciation | $3M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | · | · | · | |
| Total Assets | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | · | · | · | |
| Accounts Payable | $1M | $2M | $1M | $1M | $2M | $1M | $1M | $3M | $2M | $3M | $2M | · | · | · | |
| Current Liabilities | $8M | $10M | $13M | $12M | $9M | $6M | $8M | $10M | $9M | $11M | $9M | · | · | · | |
| Capital Leases | $0 | $45M | $46M | $47M | $48M | $48M | $48M | · | · | · | · | · | · | · | |
| Total Liabilities | $8M | $55M | $58M | $59M | $57M | $55M | $56M | · | · | · | $9M | · | · | · | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $0 | · | · | · | |
| Paid-in Capital | $363M | $360M | $358M | $357M | $356M | $354M | $352M | $350M | $348M | $10M | $9M | · | · | · | |
| Retained Earnings | $-297M | $-273M | $-260M | $-247M | $-233M | $-217M | $-201M | $-185M | $-169M | $-152M | $-136M | · | · | · | |
| AOCI | $-32.0K | $-23.0K | $64.0K | $50.0K | $-4.0K | $32.0K | $121.0K | $236.0K | $-64.0K | $-21.0K | $40.0K | · | · | · | |
| Stockholders' Equity | $66M | $86M | $99M | $110M | $123M | $137M | $151M | $165M | $179M | $-141M | $-127M | · | · | · | |
| Liabilities + Equity | $74M | $141M | $157M | $169M | $179M | $191M | $206M | $175M | $188M | $117M | $130M | · | · | · | |
| Shares Outstanding | 22,475,000 | 22,407,000 | 22,407,000 | 22,386,000 | 22,386,000 | 22,300,000 | 22,300,000 | 22,254,465 | 22,254,102 | 1,262,638 | 1,248 | · | · | · |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $284.0K | $307.0K | $310.0K | $317.0K | $317.0K | $296.0K | $262.0K | $265.0K | $263.0K | $247.0K | $200.0K | $200.0K | $200.0K | |
| Stock-based Comp | $3M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $911.0K | $883.0K | $927.0K | $615.0K | |
| Other Non-cash | · | $-3M | · | · | · | $-886.0K | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-21M | $-15M | $-10M | $-10M | $-12M | $-15M | $-16M | $-13M | $-16M | $-16M | $-12M | $-12M | $-11M | $-12M | |
| CapEx | $38.0K | $8.0K | $424.0K | $15.0K | $48.0K | $59.0K | $466.0K | $483.0K | $2M | $83.0K | $268.0K | $151.0K | $128.0K | $86.0K | |
| Investing Cash Flow | $23M | $15M | $13M | $10M | $11M | $3M | $2M | $22M | $-68M | $18M | $16M | $-8M | $-69M | $22M | |
| Financing Cash Flow | · | · | $24.0K | $0 | · | · | $113.0K | $-13.0K | $91M | $-924.0K | $-1M | $-447.0K | $100M | $31.0K | |
| Net Change in Cash | $2M | $-385.0K | $3M | $283.0K | $-420.0K | $-11M | $-14M | $9M | $6M | $1M | $3M | $-20M | $20M | $10M | |
| Free Cash Flow | · | $-15M | · | · | · | $-15M | · | · | · | $-16M | · | · | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -18.7% | -8.2% | · | -8.1% | -8.5% | -10.2% | · | -18.9% | -18.0% | -26.4% | · | · | · | · | |
| ROE | -25.1% | -12.2% | · | -10.1% | -10.4% | 686.3% | · | -20.0% | -18.9% | 21.9% | · | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.5 | 9.9 | · | 10.1 | 14.1 | 22.1 | · | 17.0 | 20.4 | 10.5 | · | · | · | · | |
| Quick Ratio | 9.3 | 9.7 | · | 9.9 | 13.8 | 21.8 | · | 16.7 | 20.0 | 9.9 | · | · | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.94 | $3.86 | · | $4.92 | $5.48 | $6.13 | · | $7.42 | $8.05 | $-111.82 | · | · | · | · | |
| Cash Flow / Share | · | $-0.67 | · | · | · | $-0.65 | · | · | · | $-12.54 | · | · | · | · | |
| Cash / Share | $0.90 | $0.78 | · | $0.67 | $0.66 | $0.68 | · | $1.81 | $1.41 | $19.91 | · | · | · | · | |
| EPS (TTM) | $-2.85 | $-2.49 | · | $7.90 | $7.78 | $7.71 | · | $-23.53 | $-33.50 | $-43.01 | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-64M | $-56M | · | $-62M | $-64M | $-66M | · | $-61M | $-58M | $-53M | · | · | · | · | |
| Market Cap | $56M | $25M | · | $28M | $23M | $34M | · | $77M | $86M | $18M | · | · | · | · | |
| P/E | -0.9 | -0.4 | · | 0.2 | 0.1 | 0.2 | · | -0.1 | -0.1 | -0.3 | · | · | · | · | |
| P/B | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | -0.1 | · | · | · | · | |
| P / Tangible Book | 0.9 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.5 | 0.5 | · | · | · | · | · | |
| P / Cash Flow | · | -1.6 | · | · | · | -2.3 | · | · | · | -1.1 | · | · | · | · | |
| Earnings Yield | -114.0% | -226.4% | · | 642.3% | 770.3% | 510.6% | · | -678.1% | -865.6% | -301.8% | · | · | · | · |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Beneficio neto | $-58M | $-65M | $-49M |
| EPS Diluido | $-2.60 | $-3.85 | $-40.65 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Ratio corriente | 8.7 | 19.0 | · |
| Ratio Rápido | 8.6 | 18.7 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Flujo de caja libre | $-47M | $-63M | · |
Propietarios institucionales (13F) 42 declarantes · $38.2M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
42
Valor en tenencia
$38.2M
Nuevas posiciones
13
Posiciones cerradas
8
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 13 (+6 vs trimestre anterior) | 8 (+2 vs trimestre anterior) | 10 (+4 vs trimestre anterior) | 9 (-1 vs trimestre anterior) | +6.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| ARCH Venture Management, LLC | $6 735 238 | 2 694 095 | 17,63% | Acciones |
| FMR LLC | $6 452 638 | 2 581 055 | 16,89% | Acciones |
| TANG CAPITAL MANAGEMENT LLC | $6 399 688 | 2 559 875 | 16,75% | Acciones |
| ADAR1 Capital Management, LLC | $4 920 540 | 1 968 216 | 12,88% | Acciones |
| Cormorant Asset Management, LP | $2 500 000 | 1 000 000 | 6,54% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 537 308 | 614 923 | 4,02% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $1 390 583 | 556 233 | 3,64% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $1 196 598 | 478 639 | 3,13% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $1 178 925 | 471 570 | 3,09% | Acciones |
| VANGUARD GROUP INC | $795 308 | 662 757 | 2,08% | Acciones |
| Alyeska Investment Group, L.P. | $750 000 | 300 000 | 1,96% | Acciones |
| Affinity Asset Advisors, LLC | $625 000 | 250 000 | 1,64% | Acciones |
| RBF Capital, LLC | $500 000 | 200 000 | 1,31% | Acciones |
| Ensign Peak Advisors, Inc | $399 588 | 159 835 | 1,05% | Acciones |
| Stonepine Capital Management, LLC | $386 488 | 154 595 | 1,01% | Acciones |
| CITADEL ADVISORS LLC | $362 623 | 145 049 | 0,95% | Acciones |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $320 000 | 128 000 | 0,84% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $291 839 | 116 736 | 0,76% | Acciones |
| BlackRock, Inc. | $221 239 | 88 495 | 0,58% | Acciones |
| PRELUDE CAPITAL MANAGEMENT, LLC | $209 995 | 83 998 | 0,55% | Acciones |
| Rangeley Capital, LLC | $185 000 | 74 000 | 0,48% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $162 840 | 65 136 | 0,43% | Acciones |
| JANE STREET GROUP, LLC | $160 807 | 64 323 | 0,42% | Acciones |
| SUPERSTRING CAPITAL MANAGEMENT LP | $138 390 | 55 356 | 0,36% | Acciones |
| NORTHERN TRUST CORP | $87 060 | 34 824 | 0,23% | Acciones |
| XTX Topco Ltd | $83 403 | 33 361 | 0,22% | Acciones |
| Qube Research & Technologies Ltd | $50 518 | 20 207 | 0,13% | Acciones |
| China Universal Asset Management Co., Ltd. | $42 250 | 16 900 | 0,11% | Acciones |
| STATE STREET CORP | $39 905 | 15 962 | 0,10% | Acciones |
| MORGAN STANLEY | $32 500 | 13 000 | 0,09% | Acciones |
| Caitong International Asset Management Co., Ltd | $26 108 | 10 443 | 0,07% | Acciones |
| Pure Financial Advisors, LLC | $25 250 | 10 100 | 0,07% | Acciones |
| Tower Research Capital LLC (TRC) | $870 | 348 | 0,00% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $440 | 176 | 0,00% | Acciones |
| JPMORGAN CHASE & CO | $439 | 179 | 0,00% | Acciones |
| ACADIAN ASSET MANAGEMENT LLC | $365 | 146 757 | 0,00% | Acciones |
| HRT FINANCIAL LP | $290 | 116 288 | 0,00% | Acciones |
| GSA CAPITAL PARTNERS LLP | $181 | 72 353 | 0,00% | Acciones |
| CWM, LLC | $9 | 8 | 0,00% | Acciones |
| Financial Management Professionals, Inc. | $5 | 2 | 0,00% | Acciones |
| UBS Group AG | $5 | 2 | 0,00% | Acciones |
| SBI Securities Co., Ltd. | $5 | 2 | 0,00% | Acciones |
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC, Robert Nelsen, Keith Crandell, Clinton Bybee, Kristina Burow, Steven Gillis | 29 de octubre de 2024 | · | Presentación inicial | Inversión pasiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 15 insiders · 8 directivos · 7 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Zachary Hornby | President & CEO | 23 de enero de 2026 A | · | 0 | 0 | $0 |
| Jami Rubin | Chief Financial Officer | 19 de agosto de 2024 A | · | 0 | 0 | $0 |
| Robert Doebele | Chief Medical Officer | 23 de enero de 2026 A | · | 0 | 0 | $0 |
| Jessica Oien | Chief Legal Officer and Corporate Secretary | 23 de enero de 2026 A | · | 0 | 0 | $0 |
| Christian Hassig | Chief Scientific Officer | 23 de enero de 2026 A | · | 0 | 0 | $0 |
| David A Hinkle | Senior VP, Finance, Controller and Treasurer | 23 de enero de 2026 A | · | 0 | 0 | $0 |
| Klaus W. Wagner | Chief Medical Officer | 19 de agosto de 2024 A | · | 0 | 0 | $0 |
| Neil Abdollahian | Chief Business Officer | 19 de agosto de 2024 A | · | 0 | 0 | $0 |
| James Christensen | Consejero | 15 de junio de 2026 A | · | 0 | 0 | $0 |
| Nancy Whiting | Consejero | 15 de junio de 2026 A | · | 0 | 0 | $0 |
| Jennifer Lew | Consejero | 15 de junio de 2026 A | · | 0 | 0 | $0 |
| Jonathan E Lim | Consejero | 15 de junio de 2026 A | 550 915 | 0 | 0 | $0 |
| Christine Brennan | Consejero | 23 de junio de 2025 A | · | 0 | 0 | $0 |
| Kristina Burow | Consejero | 23 de junio de 2025 A | 1 181 766 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Propietario del 10% | 2 de abril de 2024 C | 556 233 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 3 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
BOLD Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 6 analistas
VENTA
Objetivo mediano
$4.00
+52,7%
0 0,0%
Compra fuerte
0 0,0%
Compra
3 50,0%
Mantener
1 16,7%
Venta
2 33,3%
Venta fuerte
Precio objetivo a 12 meses
1 analistas · 2026-09-30Objetivo medio $4.00 +52,7%
Mín$4.00
Media$4.00
Máx$4.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| ACET | · | -0.5 | · | · | · | · |
| NMAD | · | · | · | · | · | · |
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 7, 2026